Sodium Iodide → (r)-5,11-Dihydro-5-[1-(3-pyrrolidinophenethyl)pyrrolidin-2-ylmethyl]dibenzo[b,e][1,4]oxazepine

Participants

Reaction Conditions

Reaction Steps

(R)-5,11-dihydro-5-(2-pyrrolidylmethyl)dibenzo[b,e][1,4]oxazepine (240 mg, 0.85 mmol, prepared by a method disclosed in International Patent No. 9912925A1), 3-pyrrolidinophenethyl mesylate (253 mg, 0.94 mmol), sodium carbonate (106 mg, 1.0 mmol) and sodium iodide (10 mg, 0.07 mmol) were added to acetonitrile (20 ml), and they were heated at 90° C. under reflux for 6.5 hours. The solvent was evaporated under reduced pressure, and the residue was distributed into ethyl acetate and saturated aqueous sodium hydrogencarbonate solution. The organic layer was washed with water and then dried over magnesium sulfate. The solvent was evaporated under reduced pressure. The obtained residue was subjected to the silica gel column chromatography. After the elution with hexane and ethyl acetate (15:1) and then with hexane and ethyl acetate (2:1) as the eluent, suitable fractions were collected and the solvent was evaporated under reduced pressure to obtain (R)-5,11-dihydro-5-[1-(3-pyrrolidinophenethyl)pyrrolidin-2-ylmethyl]dibenzo[b,e][1,4]oxazepine in the form of a light yellow oily substance (208 mg, 54%).

Provenance & Evidence